home / stock / inm / inm articles
Global X’s investment chief, Jon Maier, reflects on the investment landscape for 2024, which is shaping up to be particularly interesting, th...
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with...
Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Li...
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's ...
U.S. stocks traded slightly higher midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.17% to...
InMed Pharmaceuticals Inc (NASDAQ: INM) shares are trading higher Tuesday after the company said it selected a lead Alzheimer's drug candi...
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 250 points on Tuesday. Following the market opening Tuesday, the Dow ...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Deg...
INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for ...